Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration.

Dani B, Platz R, Tzannis ST.

J Pharm Sci. 2007 Jun;96(6):1504-17.

PMID:
17387698
2.

Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale.

Gikanga B, Turok R, Hui A, Bowen M, Stauch OB, Maa YF.

PDA J Pharm Sci Technol. 2015 Jan-Feb;69(1):59-73. doi: 10.5731/pdajpst.2015.01003.

PMID:
25691715
3.

Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.

Schüle S, Friess W, Bechtold-Peters K, Garidel P.

Eur J Pharm Biopharm. 2007 Jan;65(1):1-9. Epub 2006 Sep 1.

PMID:
17034996
4.

Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody.

Abdul-Fattah AM, Truong-Le V, Yee L, Nguyen L, Kalonia DS, Cicerone MT, Pikal MJ.

J Pharm Sci. 2007 Aug;96(8):1983-2008.

PMID:
17286290
5.

Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G.

Maury M, Murphy K, Kumar S, Mauerer A, Lee G.

Eur J Pharm Biopharm. 2005 Feb;59(2):251-61.

PMID:
15661497
6.

The impact of drying method and formulation on the physical properties and stability of methionyl human growth hormone in the amorphous solid state.

Abdul-Fattah AM, Lechuga-Ballesteros D, Kalonia DS, Pikal MJ.

J Pharm Sci. 2008 Jan;97(1):163-84.

PMID:
17722086
7.

Stabilization of IgG1 in spray-dried powders for inhalation.

Schüle S, Schulz-Fademrecht T, Garidel P, Bechtold-Peters K, Frieb W.

Eur J Pharm Biopharm. 2008 Aug;69(3):793-807. doi: 10.1016/j.ejpb.2008.02.010. Epub 2008 Feb 19.

PMID:
18477504
8.

The effect of operating and formulation variables on the morphology of spray-dried protein particles.

Maa YF, Costantino HR, Nguyen PA, Hsu CC.

Pharm Dev Technol. 1997 Aug;2(3):213-23.

PMID:
9552449
9.

Formulation and performance of danazol nano-crystalline suspensions and spray dried powders.

Kumar S, Jog R, Shen J, Zolnik B, Sadrieh N, Burgess DJ.

Pharm Res. 2015 May;32(5):1694-703. doi: 10.1007/s11095-014-1567-0. Epub 2014 Nov 11.

PMID:
25385690
10.

Characterisation of salmon calcitonin in spray-dried powder for inhalation. Effect of chitosan.

Yang M, Velaga S, Yamamoto H, Takeuchi H, Kawashima Y, Hovgaard L, van de Weert M, Frokjaer S.

Int J Pharm. 2007 Mar 1;331(2):176-81. Epub 2006 Oct 27.

PMID:
17126507
11.

Spray-freeze-drying of nanosuspensions: the manufacture of insulin particles for needle-free ballistic powder delivery.

Schiffter H, Condliffe J, Vonhoff S.

J R Soc Interface. 2010 Aug 6;7 Suppl 4:S483-500. doi: 10.1098/rsif.2010.0114.focus. Epub 2010 Jun 2.

12.

Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection.

Bowen M, Armstrong N, Maa YF.

J Pharm Sci. 2012 Dec;101(12):4433-43. doi: 10.1002/jps.23324. Epub 2012 Sep 21.

PMID:
23001898
13.

Protein inhalation powders: spray drying vs spray freeze drying.

Maa YF, Nguyen PA, Sweeney T, Shire SJ, Hsu CC.

Pharm Res. 1999 Feb;16(2):249-54.

PMID:
10100310
14.

Conversion of nanosuspensions into dry powders by spray drying: a case study.

Chaubal MV, Popescu C.

Pharm Res. 2008 Oct;25(10):2302-8. doi: 10.1007/s11095-008-9625-0. Epub 2008 May 29.

PMID:
18509597
15.

Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine.

Huang J, D'Souza AJ, Alarcon JB, Mikszta JA, Ford BM, Ferriter MS, Evans M, Stewart T, Amemiya K, Ulrich RG, Sullivan VJ.

Clin Vaccine Immunol. 2009 May;16(5):719-25. doi: 10.1128/CVI.00447-08. Epub 2009 Mar 4.

18.

Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.

Son YJ, Worth Longest P, Hindle M.

Int J Pharm. 2013 Feb 25;443(1-2):137-45. doi: 10.1016/j.ijpharm.2013.01.003. Epub 2013 Jan 10.

19.

Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying.

Sarciaux JM, Mansour S, Hageman MJ, Nail SL.

J Pharm Sci. 1999 Dec;88(12):1354-61.

PMID:
10585234
20.

Development and testing of particulate formulations for the nasal delivery of antibodies.

Kaye RS, Purewal TS, Alpar OH.

J Control Release. 2009 Apr 17;135(2):127-35. doi: 10.1016/j.jconrel.2008.11.009. Epub 2008 Nov 24.

PMID:
19059291
Items per page

Supplemental Content

Write to the Help Desk